COMMUNIQUÉS West-GlobeNewswire

Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline
11/06/2026
Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, [...]
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
11/06/2026
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activation The vaccine antigens drive specific immune responses across different human immune profiles and induce targeted [...]
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
11/06/2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant [...]
Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease
11/06/2026
Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving [...]
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
11/06/2026
ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs [...]
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
11/06/2026
Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone 1 Nearly one in three patients with stage III colon [...]
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
11/06/2026
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax [...]
Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
11/06/2026
Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at WCN 2026 Pronounced [...]
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
11/06/2026
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
CARPL.ai Partners with Enlitic to Accelerate AI Validation for Imaging Customers
11/06/2026
CUPERTINO, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- CARPL.ai, the world's largest radiology AI marketplace and enterprise platform, today announced a partnership with Enlitic, to give imaging customers a stronger [...]
Glass House Brands Announces the Filing of Shelf Prospectus and At-The-Market Distribution Program
11/06/2026
LONG BEACH, Calif. and TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“ Glass House ” or the “ Company ”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that [...]
Tilray Medical Allemagne lance ARX™, une nouvelle marque de cannabis médicinal haut de gamme cultivé en Allemagne
11/06/2026
La nouvelle marque associe des variétés éprouvées, l’expertise allemande en matière de culture et des normes de qualité rigoureuses au service des patients et des professionnels de santé dans toute l’Allemagne [...]
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
11/06/2026
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
10/06/2026
Company announcement – No. 24 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June [...]
Nyxoah Announces Closing of Underwritten Public Offering
10/06/2026
REGULATED INFORMATION Nyxoah Announces Closing of Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 10, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “ [...]
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
10/06/2026
WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock [...]
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
10/06/2026
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today [...]
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
10/06/2026
POMPANO BEACH, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue [...]
Nyxoah Annonce la Clôture de l'Offre
10/06/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Clôture de l'Offre Mont-Saint-Guibert, Belgique – 10 juin 2026, 22h05 CET / 16h05 ET - Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) (« Nyxoah » ou la « Société »), une société [...]

Pages